These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 6633756)

  • 1. Influence of aluminium on the effect of 1 alpha (OH)D3 on renal osteodystrophy.
    Shimada H; Nakamura M; Marumo F
    Nephron; 1983; 35(3):163-70. PubMed ID: 6633756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of osteitis fibrosa, aluminium bone disease and soft-tissue calcification in dialysis patients: a long-term comparison of moderate doses of oral calcium +/- Mg(OH)2 vs Al(OH)3 +/- 1 alpha OH vitamin D3.
    Morinière P; Boudailliez B; Hocine C; Belbrik S; Renaud H; Westeel PF; Solal MC; Fournier A
    Nephrol Dial Transplant; 1989; 4(12):1045-53. PubMed ID: 2517325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative evaluation of bone aluminum content and bone histology in patients on chronic hemodialysis and hemofiltration.
    Sebert JL; Fournier A; Leflon P; Fohrer P; de Frémont JF; Morinière P; Galy C; Marie A; Demontis R; Boudailliez B
    Nephron; 1986; 42(1):34-40. PubMed ID: 3941748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of hyperparathyroidism in patients on maintenance dialysis by intravenous 1-alpha-hydroxyvitamin D3 in association with Mg(OH)2 as sole phosphate binder. A randomized comparative study with the association CaCO3 +/- Mg(OH)2.
    Mornière P; Maurouard C; Boudailliez B; Westeel PF; Achard JM; Boitte F; el Esper N; Compagnon M; Maurel G; Bouillon R
    Nephron; 1992; 60(2):154-63. PubMed ID: 1552999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone aluminum deposition in maintenance dialysis patients treated with aluminium-free dialysate: role of aluminium hydroxide consumption.
    Heaf JG; Pødenphant J; Andersen JR
    Nephron; 1986; 42(3):210-6. PubMed ID: 3945361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized trial comparing 1.25 mmol/l calcium dialysate to 1.75 mmol/l calcium dialysate in CAPD patients.
    Johnson DW; Rigby RJ; McIntyre HD; Brown A; Freeman J
    Nephrol Dial Transplant; 1996 Jan; 11(1):88-93. PubMed ID: 8649658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Indirect evaluation of the effect of 1 alpha-hydroxyvitamin D3 on intestinal absorption of aluminum].
    Demontis R; Reissi D; Noël C; Morinière P; Renaud H; Leflon P; Westeel PF; Brasseur J; Coevoet B; Fournier A
    Nephrologie; 1988; 9(3):135-8. PubMed ID: 3194044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of I,25-dihydroxycholecalciferol in renal osteodystrophy.
    Silverberg DS; Bettcher KB; Dossetor JB; Overton TR; Holick MF; DeLuca HF
    Can Med Assoc J; 1975 Jan; 112(2):190, 193-5. PubMed ID: 1111876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Aluminum and uremic bone disease. Diagnostic utility of serum aluminum and the deferoxamine (DFO) test ].
    Jarava C; Armas JR; Palma A
    Nefrologia; 2001; 21(2):174-81. PubMed ID: 11464651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of 1 alpha-OH-vitamin D3 and high doses of calcium carbonate for the control of hyperparathyroidism and hyperaluminemia in patients on maintenance dialysis.
    Morinière P; Fournier A; Leflon A; Hervé M; Sebert JL; Grégoire I; Bataille P; Guéris J
    Nephron; 1985; 39(4):309-15. PubMed ID: 3982576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of 1-alpha OH D3 therapy in uremic patients in conservative or dialytic treatment.
    Lamperi S; Vagge R
    Int J Artif Organs; 1979 Sep; 2(5):243-7. PubMed ID: 478681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Aluminum in renal osteodystrophy].
    Zhu P; Wang GY; Yu YF; Zhu P
    Zhonghua Nei Ke Za Zhi; 1993 Mar; 32(3):176-8. PubMed ID: 8222983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical study of concerning factors of decreased bone mineral content in hemodialysis patients].
    Kohara N
    Nihon Jinzo Gakkai Shi; 1991 Jun; 33(6):587-96. PubMed ID: 1920939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. L-alpha-hydroxycholecalciferol treatment of adults with chronic renal failure.
    Madsen S; Olgaard K
    Acta Med Scand; 1976; 200(1-2):1-5. PubMed ID: 961464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 1 alpha-hydroxy vitamin D3 treatment of non-dialyzed patients with chronic renal failure. Effects on bone, mineral metabolism and kidney function.
    Nielsen HE; Rømer FK; Melsen F; Christensen MS; Hansen HE
    Clin Nephrol; 1980 Mar; 13(3):103-8. PubMed ID: 7379358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1 alpha OH vitamin D3 increases plasma aluminium in haemodialysed patients taking Al (OH)3.
    Fournier A; Demontis R; Tahiri Y; Herve M; Moriniere P; Leflon A; Abdull-Massih Z; Atik H; Benelmouffok S
    Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():390-4. PubMed ID: 3991529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Aluminum associated bone disease in patients undergoing long-term hemodialysis].
    Hino M; Yamamoto I; Shigeno C; Aoki J; Torizuka K; Iwamoto N; Yamazaki S; Fukuda T; Kondo M; Yamamoto N
    Nihon Naibunpi Gakkai Zasshi; 1986 Jun; 62(6):724-36. PubMed ID: 3758431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Renal osteodystrophy (3); its treatment in dialysis patients].
    Ghitu S; Oprisiu R; Benamar L; Said S; Tataru Albu A; Arsenescu I; el Esper N; Morinière P; Fournier A
    Nephrologie; 2000; 21(8):413-24. PubMed ID: 11213385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis.
    Brandi L; Daugaard H; Nielsen PK; Jensen LT; Egsmose C; Olgaard K
    Nephron; 1996; 74(1):89-103. PubMed ID: 8883025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Level-dependent inhibitory effect of hyperaluminaemia on parathyroid hormone secretion in patients with end-stage renal failure.
    Fernández E; Amoedo ML; Montoliu J
    Eur J Med; 1992 Dec; 1(8):482-4. PubMed ID: 1341207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.